DR(A-) POLYMORPHISM OF DECAY ACCELERATING FACTOR - BIOCHEMICAL, FUNCTIONAL, AND MOLECULAR CHARACTERIZATION AND PRODUCTION OF ALLELE-SPECIFIC TRANSFECTANTS

被引:40
作者
LUBLIN, DM
THOMPSON, ES
GREEN, AM
LEVENE, C
TELEN, MJ
机构
[1] DUKE UNIV,MED CTR,DEPT MED,DIV HEMATOL ONCOL,DURHAM,NC 27710
[2] GOVT CENT LABS,REFERENCE LAB IMMUNOHEMATOL,JERUSALEM,ISRAEL
[3] GOVT CENT LABS,BLOOD GRP,JERUSALEM,ISRAEL
关键词
COMPLEMENT; ERYTHROCYTES; CROMER-RELATED BLOOD GROUP; GLYCOSYL-PHOSPHATIDYLINOSITOL MEMBRANE ANCHOR; FLOW CYTOMETRY;
D O I
10.1172/JCI115220
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The Dr(a) antigen belongs to the Cromer-related blood group system, a series of antigens on decay accelerating factor (DAF), a glycosyl-phosphatidylinositol-anchored membrane protein that protects host cells from complement-mediated damage. We studied the rare inherited Dr(a-) phenotype to ascertain the associated biochemical and functional changes in DAF and to characterize the basis for this polymorphism. Radioimmunoassay and flow cytometric analysis of Dr(a-) erythrocytes demonstrated 40% of normal surface expression of DAF but normal levels of several other glycosyl-phosphatidylinositol-anchored proteins, distinguishing this phenotype from that of paroxysmal nocturnal hemoglobinuria. Western blots confirmed this reduced DAF expression and indicated a slightly faster mobility of the molecule on SDS-PAGE. Despite the reduced DAF expression, Dr(a-) erythrocytes functioned normally in the complement lysis sensitivity assay. Utilization of the polymerase chain reaction to amplify mononuclear cell genomic DNA from three unrelated Dr(a-) individuals demonstrated that a point mutation underlies the Dr(a-) phenotype: a C to T change in nucleotide 649 resulting in a serine165 to leucine change. This defines the Dr(b) allele of DAF, which can be distinguished from Dr(a) by a Taq I restriction fragment length polymorphism. We created transfected Chinese hamster ovary cell lines expressing either the Dr(a) or the Dr(b) allelic form of DAF. These allele-specific transfectants were tested by inhibition of hemagglutination or flow cytometry and confirmed the specificity of anti-Dr(a) alloantisera. The allele-specific transfectants could form the basis of a new serological approach to immunohematology.
引用
收藏
页码:1945 / 1952
页数:8
相关论文
共 57 条
[31]   IDENTIFICATION OF THE COMPLEMENT DECAY-ACCELERATING FACTOR (DAF) ON EPITHELIUM AND GLANDULAR CELLS AND IN BODY-FLUIDS [J].
MEDOF, ME ;
WALTER, EI ;
RUTGERS, JL ;
KNOWLES, DM ;
NUSSENZWEIG, V .
JOURNAL OF EXPERIMENTAL MEDICINE, 1987, 165 (03) :848-864
[32]   DECAY ACCELERATING FACTOR OF COMPLEMENT IS ANCHORED TO CELLS BY A C-TERMINAL GLYCOLIPID [J].
MEDOF, ME ;
WALTER, EI ;
ROBERTS, WL ;
HAAS, R ;
ROSENBERRY, TL .
BIOCHEMISTRY, 1986, 25 (22) :6740-6747
[33]   STUDIES ON THE SENSITIVITY TO COMPLEMENT-MEDIATED LYSIS OF ERYTHROCYTES (INAB PHENOTYPE) WITH A DEFICIENCY OF DAF (DECAY ACCELERATING FACTOR) [J].
MERRY, AH ;
RAWLINSON, VI ;
UCHIKAWA, M ;
DAHA, MR ;
SIM, RB .
BRITISH JOURNAL OF HAEMATOLOGY, 1989, 73 (02) :248-253
[34]  
NICHOLSONWELLER A, 1985, BLOOD, V65, P1237
[35]  
NICHOLSONWELLER A, 1982, J IMMUNOL, V129, P184
[36]   AFFECTED ERYTHROCYTES OF PATIENTS WITH PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA ARE DEFICIENT IN THE COMPLEMENT REGULATORY PROTEIN, DECAY ACCELERATING FACTOR [J].
NICHOLSONWELLER, A ;
MARCH, JP ;
ROSENFELD, SI ;
AUSTEN, KF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (16) :5066-5070
[37]  
PANGBURN MK, 1983, P NATL ACAD SCI USA, V82, P2980
[38]  
POST TW, 1990, J IMMUNOL, V144, P740
[39]   DECAY-ACCELERATING FACTOR - GENETIC-POLYMORPHISM AND LINKAGE TO THE RCA (REGULATOR OF COMPLEMENT ACTIVATION) GENE-CLUSTER IN HUMANS [J].
REYCAMPOS, J ;
RUBINSTEIN, P ;
DECORDOBA, SR .
JOURNAL OF EXPERIMENTAL MEDICINE, 1987, 166 (01) :246-252
[40]  
ROSSE WF, 1985, CLIN HAEMATOL, V14, P105